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STUDY QUESTION: Are there reasons that motivate young cancer survivors to ask for follow-up visits at an oncofertility unit?
SUMMARY ANSWER: Cancer survivors request oncofertility follow-up visits for the management of treatment-related side effects or
ovarian reserve evaluation, even if not (or not yet) wishing for a pregnancy.
WHAT IS KNOWN ALREADY: Personalised oncofertility counselling before gonadotoxic therapies is considered standard of care for
young women with newly diagnosed cancer. However, the long-term follow-up of these patients in an oncofertility unit is not described in the
literature other than for the use of cryopreserved material.
STUDY DESIGN, SIZE, DURATION: We retrospectively examined rates and reasons for the first follow-up visits of 154 consecutive
young female cancer patients (age range: 18–40 years) who underwent a pre-treatment consultation between January 2012 and June 2017.
Demographic and clinical data were collected, as well as information about the chosen fertility preservation method, if any.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Rates and reasons for follow-up visits were collected and expressed as
percentages. Different reasons were examined in the whole cohort and stratified for type of malignancy. Possible predictive factors for return
to the follow-up visit (age, nulliparity, presence of a partner, neoplasm, having cryopreserved material) were investigated through logistic
regression.
MAIN RESULTS AND THE ROLE OF CHANCE: Out of 154 patients, 74 returned to the oncofertility unit (48.1%) for a follow-up
visit. The first visit was requested mostly at the end of anticancer therapies (51.3% versus 40.5% during therapies and 8.1% after cancer
relapse). Among these patients, only 10.8% returned for the first time because they were actively desiring a pregnancy. For the others, the
most common reasons for consultations were management of gynecological adverse effects of therapies (29.7%) and evaluation of ovarian
reserve not linked to an immediate desire for a pregnancy (39.2%). Other patients asked for contraception (4.1%), menopause counselling
(5.4%), or new fertility preservation counselling because of cancer relapse (10.8%). None of the examined factors were significantly predictive
of return to the oncofertility unit.
LIMITATIONS, REASONS FOR CAUTION: These findings represent the experience of a single centre. A longer duration of follow-up
would be needed to provide more precise information on this regard.
WIDER IMPLICATION OF THE FINDINGS: The role of an oncofertility unit should not be limited to proposing fertility preservation
procedures. In the management of young adult cancer patients, the reproductive medical specialist should be considered a key figure not only
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Introduction
Cancer diagnosis in women of reproductive age accounts for 3–10%
of cancer worldwide (Fidler et al., 2017; Siegel et al., 2019). While
life expectations for these patients have significantly increased in the
past decades, a high proportion of them require therapies that are
potentially gonadotoxic (Lambertini et al., 2016). Cryopreservation
techniques developed for infertility treatments have been applied for
fertility preservation since the late 1990s and ultimately has led to
an increased role of oncofertility units in the management of these
patients (Diaz-Gacia et al., 2018; Cobo et al., 2018; Gellert et al., 2018;
Massarotti et al., 2017). Several scientific societies have developed spe-
cific guidelines focused on fertility preservation to underline the impor-
tance of oncofertility counselling in young women who are candidates
to potentially gonadotoxic treatments due to a newly diagnosed cancer
(Oktay et al., 2018; Peccatori et al., 2013; International Society for
Fertility Preservation, 2012; Ethics Committee of American Society for
Reproductive Medicine, 2013; ASRM, 2013b; Lambertini et al., 2017a).
While the role of reproductive medical specialists for the manage-
ment of young cancer patients is well-established at the time of diag-
nosis, the need for this professional figure during oncological follow-up
is less clear for survivors, except for those willing to undergo assisted
reproductive technology procedures using their cryopreserved mate-
rial. The utilisation rate for frozen embryos is reported to be 10–23% in
small cohorts of cancer patients (Barcroft et al., 2013; Dolmans et al.,
2015; Luke et al., 2016), and data about frozen oocytes and ovarian
tissue utilisation rates, although still incomplete and inconclusive, are
around 5% (Diaz-Garcia et al., 2018; Martinez et al., 2014; Druken-
miller et al., 2016). No other reasons for a follow-up at the oncofertility
unit are reported and its potential long-term benefits (both on repro-
ductive potential and quality of life) have gained little attention so far.
A recent study has reported that cancer survivors are more likely to
use emergency contraception than their peers (Medica et al., 2018),
opening a debate on the best way to empower them with fertility
awareness and enhancing the need for a multidisciplinary approach that
includes the fertility specialist also during oncologic follow-up (Nahata
and Quinn, 2018). Women who are not (or not yet) wishing for a
pregnancy could benefit from a long-term follow-up for managing the
gynecological adverse effects of anticancer therapies, counselling on
contraception or menopause, or evaluation of their post-treatment
ovarian reserve and reproductive potential. Moreover, data about the
real gonadotoxicity of most therapies, especially the newest targeted
agents, and the probability of premature ovarian insufficiency (POI)
are still incomplete (Lambertini et al., 2016). Indeed, not all women
who have cryopreserved will need to use their frozen gametes or
embryos to obtain a pregnancy, but they could still need the specialist
consultation for various reproductive and fertility issues. A proper
follow-up at an oncofertility unit would also allow the collection of data
about the gonadotoxicity of the new targeted agents, an issue that will













































































































In this context, it is of great relevance to understand what are
patients’ long-term requests from the reproductive medicine special-
ists. This study aims at better defining these needs by evaluating the
reasons for return to follow-up visits at an oncofertility unit.
Materials and Methods
Study design and participants
This is a retrospective analysis of prospectively collected data from
oncofertility consultations at a single oncofertility unit. The previ-
ous studies using this data received ethical approval (CERLiguria no.
032REG2013). Eligible women for this study were newly diagnosed
post-menarche cancer patients under the age of 40 years, who under-
went a pre-treatment consultation between January 2012 and June
2017. Since follow-up visits are the main focus of this study, women
deceased before having the chance to return were excluded, as were
women with severe psychiatric disorders. All patients signed a written
agreement form for the use of their data for clinical research.
Oncofertility unit
This study was conducted in a centre located within an assisted repro-
duction service, in a gynecological department of a university tertiary
hospital. The centre has an active collaboration in terms of patients’
referral from both oncologists and hematologists of all cancer services
within the same hospital and the survivorship clinic of the nearby
pediatric hospital as well as several other smaller regional institutions.
Pre-therapy consultations and follow-up visits are performed by gyne-
cologists with expertise in reproductive endocrinology and infertility,
specifically trained through internal educational sessions and multi-
disciplinary discussions of clinical cases (disease management team
meetings). Psychological support is available for all patients on request.
Study procedures
For each patient, demographic and clinical data were recorded at her
first access, along with information about ovarian reserve, the type of
fertility preservation procedure proposed, and acceptance or reasons
for refusal. The possibility of scheduling follow-up visits was offered
to all patients, regardless the patient choice on fertility preservation
techniques. The women were free to decide when and why to return
to the fertility specialist; a fast-track booking system specific for these
visits simplified the process. Information regarding the reason for the
follow-up visit was also reported.
Study objectives and statistical analysis
The primary objective was to investigate the reasons for young cancer
patients returning to a follow-up visit at an oncofertility unit after a first
consultation performed before starting anticancer therapies. In addi-
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Table 1 Characteristics of study participants: total sample and only patients who returned for a follow-up visit.
All patients (n = 154) n (%) Patients who returned for a
follow-up visit (n = 74) n (%)
.....................................................................................................................................................................................
Age at diagnosis, years 31 [26–36] 31 [27–35]
Presence of a partner at diagnosis 57.7% (89/154) 68.9% (51/74)
Nulliparity at diagnosis 85.7% (132/154) 79.8% (59/74)
Type of malignancy
Breast cancer 47.4% (73/154) 51.3% (38/74)
Hematologic cancer 31.8% (49/154) 28.4% (21/74)
Others 20.8% (33/154) 20.3% (15/74)
High gonadotoxic therapy 22.1% (34/154) 22.9% (17/74)
Ovarian reserve at diagnosis
Anti-Mullerian hormone—AMH (ng/ml) 1.77 [1.06–3.29] 1.77 [1.16–3.66]
Antral follicular count—AFC (n) 12 [8–18.5] 12 [8–17]
Fertility preservation procedures ∗
Oocyte cryopreservation ∗ 22.7% (35/154) 25.7% (19/74)
Ovarian tissue cryopreservation ∗ 11.7% (18/154) 12.2% (9/74)
Ovarian transposition ∗ 5.8% (9/154) 4.05% (3/74)
Cryopreservation procedures not proposed 25.3% (39/154) 20.2% (15/74)
GnRH agonist ∗∗ 66.8% (103/154). 67.6% (50/74)
Continuous data expressed as median [1st–3rd quartile]; categorical data expressed as percentage.
∗Some patients (n = 5) have done more than one procedure.
∗∗Of these 103 patients, 44 had used only GnRH agonists and 59 also had a cryopreservation procedure.
Continuous data are expressed as median with first and third quar-
tiles, and categorical data are expressed as absolute number and
percentage. Reasons for the first follow-up visit among subgroups of
patients affected by different malignancies were compared through chi
square test. Logistic regression was used to explore the presence of
potential predictive factors for return to follow-up. A P-value <0.05
was considered statistically significant. Statistical analysis was carried
out with the software R, version 3.5.2.
Results
Characteristics of study participants
We enrolled in the study a total of 154 women. Demographic and
clinical characteristics of the patients are reported in Table 1. The
two most common malignancies were breast (n = 73, 47.4%) and
hematological (n = 49, 31.8%) cancers. Half of the patients (n = 89,
57.7%) reported to be in a stable relationship at the time of the
first visit and the majority of them (n = 132, 85.7%) were childless.
On note, only a minority (n = 34, 22.1%) received treatments with
proven high risk of gonadotoxicity (i.e. conditioning for bone marrow
transplantation). The other patients underwent therapies with low-to-
moderate or unknown gonadotoxicity risk.
Cryopreservation procedures
In total, 57 patients (37% of the total cohort) underwent a fertility
preservation procedure. Oocyte cryopreservation was performed for































































(11.7%), and ovarian transposition for 9 patients (5.8%). Five patients
did more than one procedure. A total of 103 patients (66.8%) used
monthly injection of gonadotropin-releasing hormone (GnRH) analogs
during chemotherapy for gonadal protection. Three patients who
refused a cryopreservation procedure before a low gonadotoxicity
first-line therapy underwent ovarian tissue cryopreservation before a
second-line therapy of higher gonadotoxic potential.
Of the total sample, 39 women (25.3%) did not undergo any fer-
tility preservation procedures for medical reasons. Of the remaining
115 patients, 61 (53%) refused any cryopreservation procedure as
a personal choice. Patients flow and uptake of fertility preservation
procedures, including reasons for non-eligibility and refusal, are shown
in Fig. 1.
Return to the oncofertility unit for a
follow-up visit
Almost half of the total cohort of patients (n = 74, 48%) returned at
least once to the oncofertility unit for a follow-up visit.
Half of the patients returned to the oncofertility unit for the first time
after a mean time of 3.92 months (±2.44 months) following the end
of the anticancer therapies (51.3%), 40.5% returned during treatment,
and 8.1% returned after having experienced a relapse.
Regarding the reasons for follow-up visits, only eight patients (10.8%)
returned actively desiring a pregnancy; among these, three had a
spontaneous pregnancy, four started an ovarian stimulation for ART,
and one used her oocytes cryopreserved at the time of diagnosis.
The main reasons for the first visit were evaluation of the gonado-
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Figure 1 Patients flow and uptake of fertility preservation procedures.
FP = fertility preservation; GnRH analogs = gonadotropin-releasing hormone analogs; CHT = chemotherapy.
Figure 2 Reason for a follow-up visit, overall and according to type of malignancy.
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Table 2 Predictive factors of return to the oncofertil-
ity unit for a follow-up visit.




Being in a relationship at diagnosis 2.29 [0.94–4.65] NS
Being childless at diagnosis 0.61 [0.21–1.76] NS
Pre-treatment AMH <1 ng/ml 1.19 [0.49–2.91] NS
Breast or hematological cancer 1.53 [0.66–3.54] NS
High gonadotoxicity of therapies 1.22 [0.53–2-80] NS
Prior access to a cryopreservation
procedure
1.13 [0.55–2.30] NS
of treatment-related gynecological adverse effects (29.7%). Patients
required consultations also for counselling about contraception (4.1%)
and menopausal symptoms (5.4%). Moreover, eight patients (10.8%)
returned before starting a new and more gonadotoxic therapy for a
relapse of their malignancy.
Figure 2 shows the reasons for follow-up visits according to type of
malignancy (breast, hematological, others). The most common reason
for follow-up was management of gynecological adverse effects for
breast cancer patients and evaluation of reproductive potential for
women with hematological malignancies.
Table 2 examines possible predictive factors of return to the
oncofertility unit for a follow-up visit. Being childless, having a low
ovarian reserve at diagnosis, exposure to high gonadotoxic therapies,
type of malignancy, and a prior cryopreservation procedure were not
shown to be predictors of return to a follow-up visit.
Discussion
While the role of the oncofertility unit in counselling on infertility risk
and fertility preservation options is universally endorsed (Oktay et al.,
2018; Peccatori et al., 2013; International Society for Fertility Preser-
vation, 2012; Ethics Committee of American Society for Reproductive
Medicine, 2013; ASRM, 2013b; Lambertini et al., 2017a), less attention
is paid to its function in cancer survivors (Nahata and Quinn, 2018;
Anazodo et al., 2019), except when patients require the access to ART
procedures and the use of cryopreserved material. To our knowledge,
this is the first study reporting rates of and reasons for oncofertility
follow-up in young cancer patients, with the aim to better define a
potential broader role of the oncofertility unit in their management.
For young cancer patients, fertility is undoubtedly a relevant issue
with the majority of them showing concerns about the potential risk
of treatment-related POI and infertility after appropriate oncofertility
counselling (Lambertini et al., 2018; Ruddy et al., 2014). Undoubtedly,
the timely communication between oncologists, hematologists, and
reproductive medical specialists enables a personalised counselling
in which ovarian reserve can be evaluated, the gonadotoxicity of
therapies can be discussed, and a fertility preservation procedure
can be proposed whenever appropriate (Vu et al., 2017; Von Wolff
et al., 2015). In our experience, oncologists and hematologists give
general information about gonadotoxic risks of treatments and the





























































































































a dedicated oncofertility consultation with the reproductive medical
specialists to all women who desire more information regardless of
their attitude towards cryopreservation procedures. The acceptance
rate of cryopreservation procedures in our study seems low (49.6%);
however, notably, the majority of these patients chose not to undergo a
procedure as a conscious personal decision after complete counselling
(either because they completed their family planning or due to the low
gonadotoxicity of the proposed therapies). Nevertheless, also patients
who have completed their family planning and have no desire for other
children may be worried about the adverse effects associated with
POI development and desire reliable information about their ovarian
reserve (Vu et al., 2017; Lambertini et al., 2018). It is plausible that this
interest remains strong also during and after the end of anticancer
therapies. As suggested by our results, the ideal path of a young
woman at the oncofertility unit starts at cancer diagnosis but continues
during and after gonadotoxic therapies, and this is not only limited to
pregnancy desire or use of cryopreserved material (Fig. 3).
Various evidence in the literature shows how the needs of cancer
survivors may be not yet met by gynecologists in an optimal way
over the long term (Schover, 2018; Anderson et al., 2018). Reduced
sexual quality of life (Schover, 2018) and reduced chance of pregnancy
(Anderson et al., 2018) were observed among patients with all cancer
types, including those who underwent surgery without gonadotoxic
therapies. Gynecological adverse effects of therapies and treatment-
related loss of fertility clearly play a relevant role in these results, but
other psychological and social factors (i.e. concern about recurrence,
reproductive issues not adequately addressed, or other health issues)
may contribute (Howard-Anderson et al., 2012; Schmidt et al., 2016).
During gonadotoxic therapies, early gynecological adverse effects
are a significant issue. In the literature, cancer patients, especially
those treated with chemotherapy, report low rates of overall sexual
satisfaction and less arousal and pleasure, and these problems are
not always adequately addressed (Condorelli et al., 2019; Schover,
2018; Dominick et al., 2015). This requires specific expertise, espe-
cially in women who had hormone sensitive cancers and, therefore,
limited treatment options (American College of Obstetricians and
Gynecologists’ Committee on Gynecologic Practice and Farrell, 2016).
Coherently, 29.7% of patients returned to have a follow-up visit for
treatment-related issues (i.e. vaginal dryness or other menopausal
symptoms). This was the main reason for the return of women with
breast cancer, who are usually subjected to treatments of low-to-
moderate gonadotoxicity risk, followed by 5 to 10 years of adjuvant
endocrine therapy for hormone-sensitive cancers, which is associated
with significant side effects.
Deeply linked to this issue, and pivotal in the restoration of a
satisfactory sexual life, patients need a safe and reliable contraception.
Indeed, in the literature, data suggest that they are less likely to
receive adequate contraception counselling, with rates up to 56%
of survivors reporting no family planning counselling at all (Castro–
Sanchez et al., 2018). Additionally, they are less likely to be satisfied
and compliant with the prescribed method (Blouet et al., 2019) and
more likely to wrongly assume they are infertile and to face unwanted
pregnancies (Medica et al., 2018; Hadnott et al., 2019). Information
on contraception during chemotherapy, along with information on
fertility preservation, is part of our pre-therapy counselling. Usually,
oral combined contraceptives or a vaginal ring is suggested to patients
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Figure 3 Proposed path of young cancer patients at an oncofertility unit.
gyn = gynaecological.
contraception or copper intra-uterine device is proposed. In this study,
we reported that 4.1% of visits are exclusively for contraception
counselling; this seems low, but, since we discuss the topic at every visit,
this percentage represents only the patients who are not satisfied with
the current method and who have requested an additional consultation
to re-discuss it. More data are needed to improve the counselling of
young cancer patients on this regard.
An oncofertility unit, in our model, should manage patients over the
long term, providing education to raise fertility awareness, to obtain
the best possible sexual quality of life, to discuss the timing of a
potential pregnancy and best pathway to achieve it, or to provide
reliable contraception and gynecological care (including preventive
measures). Also in women who develop POI, the role of the reproduc-
tive specialist is crucial for the management of hormonal therapy, if not
contraindicated, or specific therapies for specific adverse effects (e.g.
sexual health, bone health) (in collaboration with endocrinologists)
and cardiovascular evaluation (with cardiologists). Indeed, a long-term
model of care enables a punctual and dynamic evaluation of reproduc-
tive potential and gonadotoxic damage of treatments at multiple time
points, with the double aim of empowering the patient with reliable
information on her ovarian reserve and to better understand the real
damage to fertility of anticancer therapies, on which we still have
little information, especially for the new targeted agents (Lambertini
et al., 2016). Surveys among gynecologists without specific expertise in
reproductive endocrinology and infertility show a generally low level of
specific knowledge and sometimes even the inability to correctly inter-
pret and contextualise hormonal levels assays in an infertile woman
(Revelli et al., 2015). Fertility evaluation post gonadotoxic therapies is
even harder for many reasons. First of all, traditional markers may be
less useful after prior exposure to gonadotoxic therapies. In fact, anti-
Mullerian hormone (AMH) levels are reported to be particularly low
right after chemotherapy, also in women with residual fertility (Freour
et al., 2017; Anderson et al., 2017). In addition, a regular menstrual
cycle is not always an indicator of fertility restoration while, on the
other hand, amenorrhea could be only temporary (Partridge et al.,
2010; Decanter et al., 2018).
The majority of women in our cohort returned for the first follow-up
visit for a reproductive potential evaluation (39.2%), and this included





















































































offered, proving how the interest remains strong also after treatments.
This was the main reason for follow-up in women with hematological
malignancies, who are subjected to therapies that span from low
gonadotoxicity (i.e. first line therapy for lymphoma with ABVD
(adriamycin/bleomycin/vinblastine/dacarbazine) regimen protocol)
to high gonadotoxicity (i.e. conditioning for bone marrow trans-
plantation). Hence, both patients who chose not to undergo a
cryopreservation procedure because of the low gonadotoxicity of the
therapies and patients who underwent high gonadotoxicity therapies
(independently of whether or not having had a cryopreservation
procedure) are both expected to desire a reproductive potential
evaluation. There is no consensus on when and how fertility
investigation after cancer therapy is predictive of future fertility. We
usually perform ovarian reserve evaluation at each visit (i.e. AMH
levels, antral follicular count, presence of menses), informing the
patient that their results, even hypergonadotropic amenorrhea, are
not conclusive of residual fertility. In our opinion, since ovarian reserve
evaluation cannot be done in a single visit and most of the markers are
dynamic and vary during and after the end of gonadotoxic therapies, a
proper follow-up at the oncofertility unit is the key for both patient’s
empowerment and advancement in scientific knowledge.
In patients who desire a pregnancy, fertility awareness enables them
to better define when and how to safely attempt a pregnancy after
cancer. The likelihood of pregnancy in women who previously had
a malignancy is reduced by ∼38% compared to the general popu-
lation (Anderson et al., 2018), in all age groups at diagnosis and in
all malignancies. The advent of new therapies and the consequently
reduced morbidity and mortality, as well fertility preservation options,
has increase the incidence of pregnancy after cancer in the last 10 years
(Anderson et al., 2018), but there is still a long way to go. The
collaboration between woman, reproductive medical specialist, and
oncologist or hematologist can minimise the risks and maximise the
chances of success, since there is actually no perfect time to try
for a pregnancy after cancer (Lambertini et al., 2017b), and only the
combination of data about the malignancy and the woman-specific
reproductive potential can lead to a pregnancy attempt, which is both
safe and effective. Thanks to the information acquired with a long-term
model of care, the patient can be adequately counselled on the best
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reproductive technologies or her cryopreserved material, or using an
oocyte donor and/or a gestational carrier). In our cohort, only 10.8%
of women returned to follow-up for the first time actively desiring a
pregnancy. Many other, included the ones who already returned for
other reasons, may try to conceive in the future, since our follow-up is
relatively short.
In conclusion, our experience suggests the needs of cancer patients
in accessing the oncofertility unit for counselling and care even when
they do not want (or cannot yet have) a pregnancy. Fertility and
gynecological health care after cancer are a result of many complex
variables and require tailored and long-term evaluation. Continuity
of care, as requested by patients in our experience, could ultimately
increase the reproductive potential, empowering women to make
conscious choices on when and how to attempt a pregnancy, if desired,
but also on effective contraception and, in general, on improving their
quality of life. Although our sample is small and reflects the experience
of a single centre, it contributes in describing the heterogeneous
needs of young cancer patients before, during and after gonadotoxic
therapies, advocating for a broader role of an oncofertility unit. With
the advancement of research in this setting, the role of the oncofertility
unit is destined to change from acute ‘rescue therapy’ to long-term
counselling and care that can and must be offered, including to women
for whom a fertility preservation procedure is not indicated or not
requested.
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